(Total Views: 621)
Posted On: 05/05/2022 10:30:22 PM
Post# of 148878
CYDY vs NWBO question: Not a bash on NWBO, but why do they enjoy about 2x the market cap of CYDY?
I know they recently had about a 2x runup, but I'm surprised that Leronlimab, with its myriad of possible treatable diseases, is not valued higher, since both companies seem to be at roughly the same stage.
My first thought is to blame the shorting, I believe the BP's have much more to lose from CYDY's first FDA approval vs NWBO's.
Bottom line, once we get that first approval or partnerships and the results turn out as well as evidence seems to suggest, CYDY can be absolutely huge. I know I'm preaching to the choir, but this LL stuff with no SAE's seems just incredible.
I know they recently had about a 2x runup, but I'm surprised that Leronlimab, with its myriad of possible treatable diseases, is not valued higher, since both companies seem to be at roughly the same stage.
My first thought is to blame the shorting, I believe the BP's have much more to lose from CYDY's first FDA approval vs NWBO's.
Bottom line, once we get that first approval or partnerships and the results turn out as well as evidence seems to suggest, CYDY can be absolutely huge. I know I'm preaching to the choir, but this LL stuff with no SAE's seems just incredible.
(3)
(0)Scroll down for more posts ▼
